Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FCN 159

Next Previous
X
Search
Drug Profile

FCN 159

Alternative Names: FCN-159

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Fochon Pharmaceutical
  • Developer Chongqing Fochon Pharmaceutical; Shanghai Fosun Pharmaceutical
  • Class Antineoplastics; Small molecules; Vascular disorder therapies
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plexiform neurofibroma
  • Phase II Glioma; Histiocytosis; Neurofibromatosis 1
  • Research Vascular disorders
  • No development reported Malignant melanoma; Solid tumours

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (PO, Tablet)
  • 13 Jun 2024 Efficacy and adverse events data from phase II clinical trials in Histiocytosis presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 31 May 2024 Efficacy and adverse event data from a phase I/II trial in Neurofibromatosis 1 presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top